



INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/540,344		ATTY. DOCKET NO.: M0765.70047US01	
		FILING DATE: May 15, 2006		CONFIRMATION NO.: 6440	
		APPLICANT: Eng H. Lo et al.			
		GROUP ART UNIT: 1646 1649		EXAMINER: Not Yet Assigned	
Sheet	1	of	3		

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
SC	A1	4,766,075		David V. Goeddel et al.	08-23-1988
11	A2	2005-0019329	A1	Lawrence et al.	05-20-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
SC	B1	WO	93/24635				
11	B2	EP	339,505	A			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
SC	C1	AHERN, T.J. et al., Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation. J Biol Chem. 265(10): 5540-5545, 1990.	
11	C2	ALBERS et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 483S-512S, 2004.	
11	C3	AOKI, T., et al., Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33:2711-2717, 2002.	
11	C4	ASAHI, M., et al., Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681-1690, 2000.	
11	C5	ASAHI, M., et al., Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732, 2001.	
11	C6	BESCHORNER, R., et al., Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans. Neuropath. Appl. Neurobiol. 26:522-527, 2000.	
11	C7	HACKE, W. et al., Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA 274:1017-1025, 1995.	
11	C8	HACKE W, et. al., Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53 (Suppl 4):s3-s15, 1999.	

56	C9	HAHN-DANTONA, et al., The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J. Biol. Chem. 276(18):15498-15503, 2001.	
11	C10	HERZ, J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron. 29(3): 571-581, 2001.	
11	C11	HOTCHKISS, A. et al., The activity of a single chain rt-PA mutant in a primates and rabbits. Throm. Haemostas 55: 491, 1987.	
11	C12	LAPCHAK et al., Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke, 31:3034-3040, 2000.	
11	C13	JOHANNESSEN, M. et al., Fibrin affinity and clearance of t-PA deletion and substitution analogues. Thromb Haemost. 63(1): 54-59, 1990.	
11	C14	LARRUE V, et. al., Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 28:957-960, 1999.	
11	C15	LO et al., Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. 69:1-9, 2002.	
11	C16	MARTIN, U. et al., Thrombolytic potency of an E. Coli-produced novel variant of rt-PA in dogs. Fibrinolysis 4: 9, 1990.	
11	C17	MONTANER et al., Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759-1766, 2001.	
11	C18	MONTANER, et. al, Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke, 32:2762-2767, 2001.	
11	C19	MORI T., et al., Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J. Neurotrauma 19(11):1411-1419, 2002.	
11	C20	NINDS rt-PA Stroke Study Group, Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. New Engl J Med 333:1581-1587, 1995.	
11	C21	NINDS rt-PA Stroke Study Group, Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 28:2109-2118, 1997.	
11	C22	SOBEL, B.E. et al., Augmented and sustained plasma concentrations after intramuscular injections of molecular variants and deglycosylated forms of tissue-type plasminogen activators. Circulation. 81(4): 1362-1373, 1990.	
11	C23	SUMII, T., and E.H. Lo, Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831-836, 2002.	
11	C24	SUZUKI, S. et al., Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity. J Cardiovasc Pharmacol. 1993 22(6): 834-840, 1993.	
11	C25	WANG X, et al., Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures. Neurosci Lett 274:79-82, 1999.	
11	C26	WILLNOW, T.E. et al., Lipoprotein receptors: new roles for ancient proteins. Nat Cell Biol. 1(6): E157-E162, 1999.	

56	C27	ZHANG et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106(6): 740-745, 2002.	

EXAMINER: <i>Stephen Gudder</i>	DATE CONSIDERED: <i>11/26/07</i>
---------------------------------	----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]